Aurobindo Pharma Reports Strong Q1 FY27 Results, Driven by Revenue Growth and Global Market Performance

Aurobindo Pharma Reports Strong Q1 FY27 Results, Driven by Revenue Growth and Global Market Performance​

Aurobindo Pharma Limited announced its consolidated financial results for the first quarter ended June 30, 2026. The company reported a Net Profit of INR 1,032 Cr and a total Revenue from Operations of INR 9,150 Cr, marking significant growth across key segments.

The company's performance details are summarized below:

Q1 FY27 Performance Highlights​

Key operational highlights from Aurobindo Pharma Limited for the first quarter include:

• Revenue Growth: Revenue from Operations increased by 16.3% year-over-year (YoY), reaching INR 9,150 Cr.
• Geographic Expansion: The company saw robust growth across international markets, with Europe revenue increasing by 25.6% YoY to INR 2,937 Cr (EUR 267 million). Growth Markets revenue surged by 37.7% YoY, reaching INR 1,063 Cr (USD 113 million).
• US Operations: US revenue grew by 8.1% YoY to INR 3,770 Cr (USD 399 million), driven by volume gains and new product launches.
• Financial Strength: The company maintained a strong net cash position of USD 42mn as of June 30, 2026, after accounting for the Lannett acquisition payment of USD 247mn and a buyback of USD 85mn. It also generated free cash flow of USD 98mn during the quarter.
• Product Approvals: Aurobindo Pharma Limited received final approval from USFDA for 10 products, including Canagliflozin Tablets (Anti-Diabetic), Pirfenidone Capsules (Antifibrotic Agent), and Dapagliflozin Tablets (Anti-Diabetic).

Operational Performance by Business Area​

Consolidated operational performance showed Formulations revenue reaching INR 8,101 Cr, which is a 16.5% increase YoY from the Q4FY26 figure of INR 7,646 Cr.

The breakdown across major geographical segments and business areas is provided in the table below:


Apart from Formulations, API revenues stood at INR 1,049 Cr, which is a 14.6% increase YoY. ARV revenue was reported at INR 330 Cr, representing 3.6% of consolidated revenue for the quarter.

Management Commentary​

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company, stated, "We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders."

Future Engagement​

The company is scheduled to host an earnings call on August 6, 2026, at 8:30 AM IST to discuss the performance and answer participant questions.

AUROPHARMA Stock Price Movement​

Today, Aurobindo Pharma Limited shares edged higher to settle at ₹1613.4 after closing, gaining 1.73% in the session. The stock traded within an intraday range of ₹1567 to ₹1625, as over 1.38 million shares were transacted.